Viridian Therapeutics
VRDN
Market cap $1.83B

23.92 USD

+0.04

0.17%

At close Oct 4, 4:00 PM EDT

After hours

24.22

+0.30

1.25%

1 day

0.17%

5 days

5.14%

1 month

69.77%

3 months

94.31%

6 months

41.54%

Year to date

7.02%

1 year

69.89%

5 years

115.30%

About: Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.

Employees: 94

Healthcare Medical Laboratories

0

Funds holding %

of 6,728 funds

0

Analysts bullish %

of 13 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

146% more repeat investments, than reductions

Existing positions increased: 69 | Existing positions reduced: 28

11% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 18

1% more funds holding

Funds holding: 134 [Q1] → 136 (+2) [Q2]

5.37% less ownership

Funds ownership: 114.26% [Q1] → 108.9% (-5.37%) [Q2]

28% less capital invested

Capital invested by funds: $1.26B [Q1] → $904M (-$352M) [Q2]

42% less call options, than puts

Call options by funds: $3.99M | Put options by funds: $6.92M

80% less funds holding in top 10

Funds holding in top 10: 5 [Q1] → 1 (-4) [Q2]

See Fund Rankings

Research analyst outlook

13 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$27

13%

upside

Avg. target

$38

58%

upside

High target

$61

155%

upside

13 analyst ratings

13 positive

100%

0 neutral

0%

0 negative

0%

BTIG Julian Harrison 56% 1-year accuracy 9 / 16 met price target	155%upside $61	Buy Maintained	26 Sept 2024
RBC Capital Gregory Renza 44% 1-year accuracy 35 / 79 met price target	84%upside $44	Outperform Reiterated	19 Sept 2024
RBC Capital Gregory Renza 44% 1-year accuracy 35 / 79 met price target	84%upside $44	Outperform Maintained	13 Sept 2024
Goldman Sachs Richard Law 75% 1-year accuracy 3 / 4 met price target	30%upside $31	Buy Maintained	12 Sept 2024
Needham Serge Belanger 50% 1-year accuracy 57 / 115 met price target	59%upside $38	Buy Maintained	11 Sept 2024

See Analyst Rankings

Financial journalist opinion

Based on 10 articles about VRDN published over the past 30 days

3 Small Biotech Stocks With The 'Big Mo' Right Now

Three small biotech stocks that I have covered lately have shown significant upward movement recently due to positive news. The stocks are experiencing what I call the 'Big Mo,' indicating strong momentum that could lead to additional upward movement. We follow up on these three small biotech/biopharma names and bring followers up to date on the recent positive news flow around them in the paragraphs below.

3 Small Biotech Stocks With The 'Big Mo' Right Now

Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced the pricing of an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors, shares of Series B non-voting convertible preferred stock. Viridian is selling a total of 10,666,600 shares of common stock at a public offering price.

Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock

Zacks Investment Research

VRDN Stock Soars as Eye Disorder Study Meets Primary Endpoints

The phase III THRIVE study evaluating Viridian's veligrotug for treating active thyroid eye disease meets all primary and secondary endpoints.

VRDN Stock Soars as Eye Disorder Study Meets Primary Endpoints

Viridian: Active TED Data Signifies Next Round Of Positive Data On The Way

Viridian Therapeutics, Inc. reported that the primary endpoint was met for the phase 3 THRIVE study, using veligrotug for the treatment of patients with active thyroid eye disease. Data release for THRIVE-2 study, using veligrotug for the treatment of patients with chronic thyroid eye disease, expected end of 2024. It is expected that the 7 major thyroid eye disease markets will reach $4.13 billion by 2034.

Viridian: Active TED Data Signifies Next Round Of Positive Data On The Way

Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that it has commenced an underwritten public offering of $150 million of shares of its common stock and Series B non-voting convertible preferred stock. All of the securities to be sold in the underwritten public offering are being offered by Viridian. In addition, Viridian inte.

Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock

Schaeffers Research

Biotech Stock Scores Big Win, Squeezes Shorts

Viridian Therapeutics Inc (NASDAQ:VRDN) stock is up 11.1% to trade at $15.75 today, and earlier traded as high as $16.35, after the biotech company's eye disorder treatment met the main goal of a late-stage study.

Biotech Stock Scores Big Win, Squeezes Shorts

Investors Business Daily

Viridian Spikes On A 'Bull-Case Scenario' For Eye Drug Considered Amgen Rival

Viridian Therapeutics stock jumped Tuesday after unveiling promising results for its Amgen-rivaling eye disease treatment.

Viridian Spikes On A 'Bull-Case Scenario' For Eye Drug Considered Amgen Rival

Viridian Therapeutics' eye disorder treatment meets main goal in late-stage study

Viridian Therapeutics said on Tuesday its experimental drug to treat patients with thyroid eye disease significantly reduced bulging of the eye in a late-stage study.

Viridian Therapeutics' eye disorder treatment meets main goal in late-stage study

Viridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced positive topline data from the THRIVE phase 3 clinical trial of VRDN-001, now known as veligrotug, an intravenously delivered anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, in patients with active thyroid eye disease (TED). TED is an autoimmune condition chara.

Viridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease

Viridian Therapeutics to Webcast VRDN-001 Phase 3 THRIVE Topline Results on September 10, 2024

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, will host a conference call and webcast to report topline data for the THRIVE phase 3 clinical trial, evaluating VRDN-001 in patients with active TED, on Tuesday, September 10, 2024 at 8:00am ET. Conference call and webcast information The webcast can be accessed under “Events and Presentat.

Viridian Therapeutics to Webcast VRDN-001 Phase 3 THRIVE Topline Results on September 10, 2024

See News Rankings

Charts implemented using Lightweight Charts™